RedHill Biopharma

[Not Yet Scheduled]
RedHill Biopharma Ltd. (Nasdaq: RDHL) is a specialty biopharmaceutical company, primarily focused on the commercialization and development of proprietary drugs for the treatment of gastrointestinal diseases. RedHill commercializes and promotes several gastrointestinal products in the U.S. and is planning to launch Talicia® in the U.S. for the treatment of Helicobacter pylori (H. pylori) infection in adults. RedHill’s key clinical late-stage development programs include: RHB-104, RHB-204, RHB-102 (Bekinda®), ABC294640 (Yeliva®), RHB-106 and RHB-107. More information about the Company is available at www.redhillbio.com.
Ticker:
RDHL
Exchange:
Nasdaq
Company Type:
Publicly Traded Company
Company Website:
Company HQ State:
Not Provided
Company HQ Country:
Israel
Year Founded:
Not Provided
Main Therapeutic Focus:
Lead Product in Development:
Talicia (H.pylori)
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided
Speaker
photo
Senior VP Business Development and Licensing
RedHill Biopharma